BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會


2022 Regional Collaboration Forum


BIO Asia–Taiwan 2022
Regional Collaboration Forum Agenda 

Date July 27-31|On-demand

Venue Online event platform

Session 16 - AFOB
Session 17 - Australia
Session 18 - India
Session 19 - Japan
Session 20 - Singapore
Session 21 - UK
Session 22 - Lithuania

AFOB Net Zero Emission Bioeconomy


Bioeconomy is defined as “an economy where the basic building blocks for materials, chemicals, and energy are derived from renewable biological resources.”

15 mins

Biotechnology in Carbon Recycling Society
Yutaka Nakashimada, Professor, Graduate School of Integrated Sciences for Life, Hiroshima University, Japan

30 mins

The Australian Biotechnology Ecosystem


Australia is a powerhouse for science and innovation, with excellent research facilities and a strong but flexible regulatory regime for pharmaceutical innovation. Australia is also regarded as one of the best places in the world to conduct clinical trials, with strengths in oncology, neurology and ophthalmology. This session will highlight the vibrant health and medical research ecosystem in Australia, featuring Australian state showcases to highlight the Australian health and biomedical ecosystem. As an innovative biotech leader, Australia is an ideal environment to research, develop and scale personalized medicines.

10 mins

Opening Remarks

Jenny Bloomfield, Representative, Australian Office

5 mins

Queensland Showcase

Life Science Queensland

5 mins

New South Wales Showcase

Investment NSW

5 mins

Victoria Showcase


5 mins

South Australia Showcase

South Australia, Department for Trade and Investment

5 mins

Western Australia Showcase

Western Australia Life Science Innovation

India – A Reliable Partner for the World


During the Covid pandemic years, India’s biotech companies demonstrated global leadership by producing over 2 billion doses of various COVID-19 vaccines and adding to the availability to vulnerable countries without vaccine manufacturing capabilities through the Covax program.

Biotechnology research and development is a complex, long gestation and resource intensive process. Also, innovation and speed are essential and companies seek to de-risk development and manufacturing costs by using competent partners around the world. India’s biotechnology companies are filling the global need for Contract Development and Manufacturing Organizations (CDMOs) for a wide range of biopharma products. India’s biotech CDMOs are emerging as reliable partners to help the global pharmaceutical industry with their specialized expertise in manufacturing and various steps involved in the entire value chain as affordable and reliable partners to lower the risk of capital deployment. This session will show case FOUR such companies from India that offer, with their integrated facilities across the biotech/pharma value chain, a wide range of development and manufacturing capabilities as reliable partners to the global pharmaceutical industry.

Why India is an attractive Biotech global destination

Dr. P M Murali, President, ABLE Council of Presidents

Biocon Biologics

Susheel Umesh, Chief Commercial Officer- Emerging Markets, Biocon Biologics

Japan – Bioeconomy Strategy and Open Innovation in Japan


The exponential advancement of biotechnology in recent years has enabled its application in all industrial sectors, and under the name of the bioeconomy, while aiming to expand its market, it is increasingly being used as a means to solve numerous social issues. In line with this growing importance of the bioeconomy, the government of Japan has released the Bioeconomy Strategy in 2019, concentrating on the formation of networks and the promotion of open innovation based on the biocommunity as one of its focused points. In addition, pharmaceutical and other companies, which are aggressively seeking to enhance their own R&D activities through open innovation, are increasing their importance of alliances with other companies and networks for finding partners. In light of this circumstances, we have planned this session to introduce Japan's Bioeconomy Strategy and the activities of the two global biocommunities formed in accordance with this strategy, and to have two leading Japanese pharmaceutical companies speak about their open innovations. We hope that session will help you accelerate collaborations with Japanese organizations and companies.

5 mins

Closing Remarks

Yoshiaki Tsukamoto, Executive Director, Japan Bioindustry Association

Singapore Biotech Ecosystem: Past, Present and Future


This session showcases the rapidly evolving Singapore biotech ecosystem, focus areas, growing funding and vast support network. Further, the session will showcase four successful homegrown Singapore biotech companies: Hummingbird Bioscience, Engine Biosciences, DotBio and MediSix Therapeutics.

Singapore Biotech Ecosystem

Danny Soon, Chief Executive Officer, Consortium for Clinical Research and Innovation Singapore; Executive Director, Singapore Clinical Research Institute

Company Showcase: Hummingbird Bioscience

Company Showcase: Engine Biosciences

Company Showcase: DotBio

Company Showcase: MediSix Therapeutics

Life Science Ventures in UK


The UK has long been a world-leader for innovation in life sciences. That is why so many of the great breakthroughs in this field – like Sir Alexander Fleming’s discovery of penicillin and the discovery of the structure of DNA and antibody therapies – have happened here. With advances in our understanding of biological systems, higher-speed computing and breakthroughs in genomics, we have opened up untold possibilities and more. The UK’s rich history as a centre for science and innovation in Life Sciences is underpinned by long-standing infrastructure investments by the National Institute for Health Research (NIHR), UK Research and Innovation (UKRI) and the medical research charities; the deep science skills base across industry, academia, the NHS; and the ingenuity and drive of industry – from the world’s largest Life Sciences companies to the smallest SMEs.

In this video, we will explain why choose UK life sciences and also showcasing 9 UK innovations listed in alphabetical order- AMT, Astrazeneca, Evaluate, GSK, Gyrogear, iotaSciences, Leo Cancer Care, Oxford Instruments and Yourgene Health.


Regional Collaboration Forum Opening Speech

Charlotte Mackay, British Office Taipei


Why Choose UK Life Sciences

British Office Taipei - Department for International Trade


Company Presentation: Astrazeneca


Company Presentation: iotaSciences


Company Presentation: Evaluate

Amy Brown, Deputy Editor, Evaluate Vantage Cem Baydar, Chief Consulting Officer, Evaluate


Company Presentation: Yourgene Health


Company Presentation: GSK

Mick Stanley, General Manager, GlaxoSmithKline Taiwan

Session Speaker

Mrs. Karolina Karl – Head of Life Sciences team, Invest Lithuania



Lithuania, a small Baltic nation with a population of around 2.8 million people, has shifted its focus to Life Sciences. In this session, governmental agency responsible for attracting foreign direct investment to the country - Invest Lithuania’s, Head of Life Sciences team Karolina Karl will discuss Lithuania’s journey to becoming an independent state driven by innovation and how Life Sciences are seen as a key part of the national strategy for future economic growth. With this aim, the government set an ambitious goal to increase the GDP contribution of the Life Sciences industry from 2.5% to 5% by 2030.

To date, Lithuania has built a well-functioning business ecosystem where it takes only a few days to register a biotech company or get construction permits, all through digitalized systems aligned with EU regulations and norms. The Baltic champion also offers some of the most competitive FDI tax incentives in Europe, including one of the lowest patent box tax as well as 20 years corporate profit tax release for large scale investments. Multinational companies including Thermo Fisher, Hollister, Dexcom, Esco, Teva and others have already taken advantage of the unbeatable conditions and world-class talent pool available locally.

This session will illustrate what Lithuania can offer through stories covering the research of a local Vilnius University Professor Virginijus Siksnys, who was one of the co-founders of the CRISPR Cas9 technology, alongside Nobel Prize winners Emmanuelle Charpentier and Jennifer A. Doudna. In addition to that, you will get to know what drug was developed by Teva’s Lithuanian team and how Thermo Fisher has been growing in the market for the last 20 years.

Come and explore a new gateway to Europe!